BIO Quote, Financials, Valuation and Earnings

Bionano Genomics, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -115.42%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 15.6%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 390.2%. Given that Bionano Genomics, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.25x versus 0.18x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -6.8%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bruker Corp.'s return on equity of -1.2%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 15.6%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 7.84%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Bruker Corp., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Bruker Corp..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bruker Corp.'s net income of -$58.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.25x versus 2.13x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -5.98%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 15.6%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 175.71%. Given that Harvard Bioscience, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.25x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies Ltd. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -145.29%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 15.6%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.14 which suggests that it could grow by 5.9%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Kestra Medical Technologies Ltd..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.25x versus 19.03x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.